Spots Global Cancer Trial Database for First-line Treatment With RC48 Plus Tislelizumab and S-1(RCTS) in Advanced Gastric Cancer
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: First-line Treatment With RC48 Plus Tislelizumab and S-1(RCTS) in Advanced Gastric Cancer
Official Title: A Prospective, Multicenter, Phase II Clinical Study of First-line Treatment for HER2 (Human Epidermal Growth Factor Receptor 2) Positive Advanced Gastric Cancer With Disitamab Vedotin in Combination With Tirelizumab and S-1
Study ID: NCT05586061
Conditions
Study Description
Brief Summary: This is a prospective, single arm, multicenter phase II study aimed at evaluating the efficacy and safety of Disitamab Vedotin in Combination With Tirelizumab and S-1 as first-line treatment for patients with advanced HER2-positive gastric or gastroesophageal junction adenocarcinoma.
Detailed Description:
Keywords
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
Central Hospital Affiliated to Shandong First Medical University, Jinan, Shandong, China
Qilu Hospital of Shandong University, Jinan, Shandong, China
Shandong Provincial Hospital Affiliated to Shandong First Medical Universiry, Jinan, Shandong, China
The First Affiliated Hospital of Shandong First Medical University (Shandong Provincial Qianfoshan Hospital), Jinan, Shandong, China
The Affiliated Hospital of Qingdao University, Qingdao, Shandong, China
Qingdao Municipal Hospital (Group), Qingdao, Shandong, China
Yantai Yuhuangding Hospital, Yantai, Shandong, China
Contact Details
Name: Lian Liu, Doctor
Affiliation: Qilu Hospital of Shandong University
Role: PRINCIPAL_INVESTIGATOR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
